



# WHO Training Course on Adjuvants and Vaccine Formulation 15 – 19 June 2015, University of Lausanne

## Monday, 15 June 2015

	<b>1. Welcome session</b>
08:30 – 09:00	<i>Registration</i>
09:00 – 09:15	Welcome <b>Nicolas Collin</b> , University of Lausanne, Switzerland
09:15 – 09:30	Introduction to the course <b>Maria Lawrenz</b> , University of Lausanne, Switzerland
	<b>2. Introduction to vaccine adjuvants</b>
09:30 – 11:00	Vaccine development <b>Birgitte Giersing</b> , World Health Organization, Geneva, Switzerland
11:00 – 11:30	<i>Coffee break</i>
11:30 – 12:30	Past and present of vaccine adjuvants <b>Virgil Schijns</b> , University of Wageningen, The Netherlands
12:30 – 13:30	<b>Discussion:</b> Bright future for adjuvants?
13:30 – 14:30	<i>Lunch</i>
	<b>3. Vaccine formulation</b>
14:30 – 15:00	Importance of vaccine formulation <b>Christophe Barnier-Quer</b> , University of Lausanne, Switzerland
15:00 – 15:30	Chemistry of vaccine formulation <b>Livia Brunner</b> , University of Lausanne, Switzerland
15:30 – 16:30	<b>Networking:</b> Participant's introduction





## WHO Training Course on Adjuvants and Vaccine Formulation 15 – 19 June 2015, University of Lausanne

### Tuesday, 16 June 2015

	<b>4. Adjuvant systems – part I</b>
09:00 – 10:00	Oil-in-water emulsions <b>Sylvie Bertholet</b> , Novartis Vaccines and Diagnostics (GSK), Siena, Italy
10:00 – 11:00	Water-in-oil emulsions <b>Stéphane Ascarateil</b> , SEPPIC, Paris, France
11:00 – 11:30	<i>Coffee break</i>
11:30 – 12:00	<b>Lab demonstration:</b> Preparation of emulsion adjuvants <b>VFL team</b> , University of Lausanne, Switzerland
12:00 – 13:30	<i>Lunch</i>
13:30 – 14:30	Aluminium salts <b>Erik Lindblad</b> , Brenntag, Frederikssund, Denmark
14:30 – 15:00	Toll like receptor ligands as vaccine adjuvants <b>Christian Hotz</b> , University of Fribourg, Switzerland
15:00 – 15:30	<i>Coffee break</i>
15:30 – 16:30	Liposomes <b>Dennis Christensen</b> , Statens Serum Institute, Copenhagen, Denmark
16:30 – 17:00	<b>Lab demonstration:</b> Preparation of liposomes <b>VFL team</b> , University of Lausanne, Switzerland

### Wednesday, 17 June 2015

	<b>5. Adjuvant systems – part II</b>
09:00 – 10:00	QS21, ISCOMs and other clinically relevant adjuvants <b>Anita Milicic</b> , University of Oxford, United Kingdom
10:00 – 11:00	Virosomes <b>Sylvain Fleury</b> , Mymetics, Lausanne, Switzerland
11:00 – 11:30	<i>Coffee break</i>
11:30 – 12:30	Adjuvant properties of PLG Particles <b>Ed Lavelle</b> , Trinity College Dublin, Ireland
12:30 – 14:00	<i>Lunch</i>
<b>6. Mucosal adjuvants</b>	
14:00 – 15:00	Mucosal vaccines <b>Stéphane Paul</b> , CHU Saint Etienne, France
15:00 – 16:00	Mucosal adjuvants <b>Thorunn Asta Olafsdottir</b> , University of Gothenburg, Sweden
19:00	<i>Social Dinner</i>





## WHO Training Course on Adjuvants and Vaccine Formulation 15 – 19 June 2015, University of Lausanne

Thursday, 18 June 2015

	<b>7. Preclinical development</b>
08:30 – 09:00	Preclinical development introduction <b>Eddy Rommel</b> , Rommel Consulting Partners, Jodoigne, Belgium
09:00 – 10:00	Animal models and immunogenicity readout <b>Patrice Dubois</b> , University of Lausanne, Switzerland
10:00 – 11:00	Safety evaluation <b>Eddy Rommel</b> , Rommel Consulting Partners, Jodoigne, Belgium
11:00 – 12:30	<b>Practical exercise I: Case studies (parallel sessions)</b> Group 1: Preclinical safety testing <b>Eddy Rommel</b> , Rommel Consulting Partners, Jodoigne, Belgium Group 2: Primary pharmacodynamics testing <b>Patrice Dubois</b> , University of Lausanne, Switzerland
12:30 – 13:30	<i>Lunch</i>
13:30 – 15:30	Parallel sessions - continued
15:30 – 16:00	<i>Coffee break</i>
16:00 – 17:00	Presentation of case studies <b>Participant groups 1 and 2</b>





## WHO Training Course on Adjuvants and Vaccine Formulation 15 – 19 June 2015, University of Lausanne

**Friday, 19 June 2015**

	<b>8. Clinical development</b>
09:30 – 10:30	Clinical evaluation of adjuvanted vaccines <b>Nathalie Garçon</b> , BIOASTER Technology Research Institute, Lyon, France
	<b>9. Regulatory aspects</b>
10:30 – 11:00	Registration of adjuvanted vaccines <b>Pieter Neels</b> , Vaccine-Advise, Brussels, Belgium
11:00 – 11:30	<i>Coffee break</i>
11:30 – 13:00	<b>Practical exercise II: An adjuvanted Hepatitis B vaccine</b> Group 1: Industry <b>Nathalie Garçon</b> , BIOASTER Technology Research Institute, Lyon, France Group 2: Regulators <b>Pieter Neels</b> , Vaccine-Advise, Brussels, Belgium Panel discussion <b>Participants</b>
13:00 – 14:30	<i>Lunch</i>
14:30 – 16:00	<b>Practical exercise III: An adjuvanted IPV vaccine</b> Group 1: Regulators <b>Pieter Neels</b> , Vaccine-Advise, Brussels, Belgium Group 2: Industry <b>Nathalie Garçon</b> , BIOASTER Technology Research Institute, Lyon, France Panel discussion <b>Participants</b>
16:00 – 16:30	<i>Coffee break</i>
16:30 – 17:00	<b>10. Evaluation of the course and Certification</b>

